30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease

被引:39
作者
Osti, M. F. [1 ]
Agolli, L. [2 ,3 ]
Valeriani, M. [1 ]
Reverberi, C. [1 ]
Bracci, S. [1 ]
Marinelli, L. [1 ]
De Sanctis, V. [1 ]
Cortesi, E. [4 ]
Martelli, M. [5 ]
De Dominicis, C. [6 ]
Minniti, G. [7 ,8 ]
Nicosia, L. [1 ]
机构
[1] Sapienza Univ Rome, St Andrea Hosp, Dept Radiat Oncol, Rome, Italy
[2] Tech Univ Dresden, Fac Med, Dept Radiat Oncol, Dresden, Germany
[3] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany
[4] Sapienza Univ Rome, Policlin Umberto 1, Dept Radiol Oncol & Human Pathol, Rome, Italy
[5] Carlo Forlanini Hosp, Thorac Surg Unit, Rome, Italy
[6] Sapienza Univ Rome, St Andrea Hosp, Dept Radiol, Rome, Italy
[7] IRCCS Neuromed, Dept Neurol Sci, Via Atinense, Pozzilli, IS, Italy
[8] UPMC San Pietro FBF, Radiotherapy Ctr, Rome, Italy
关键词
Single dose stereotactic radiotherapy; Oligometastatic lung; Tumors; Local control; Adverse affects; CANCER; RADIOTHERAPY; IRRADIATION; SCHEDULES; SURVIVAL; TUMORS;
D O I
10.1016/j.lungcan.2018.06.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To evaluate the local control (LC) and long term adverse effects in a series of patients with lung metastases who received 30 Gy in single dose with stereotactic technique. Materials and Methods: Between December 2008 and April 2016, a total of 166 lung metastases in 129 patients affected by oligometastatic disease were treated at our Institution with stereotactic body radiotherapy (SBRT). Mainly, the primary tumors were non small-cell lung cancer and colorectal cancer (45.2% and 28.8%, respectively). Prognostic factors were also assessed. Results: The median follow-up was 38 months. Local progression occurred in 24 (14.4%) lesions in 21 patients. Intra-thoracic progression (new lung lesions or thoracic lymph node metastases) occurred in 59 (45.7%) patients. Forty-five (34.8%) patients had distant progression after a median time of 14 months. The 3- and 5-years local relapse-free survival (LPFS) were 80.1% and 79.2% (median not reached), respectively. One-hundred fortyeight patients were evaluated for late toxicity (follow-up >6 months): 51 (34.4%) patients had grade <= 2 fibrosis, 11 (7.4%) patients experienced grade 3 fibrosis. Two (1.3%) cases of rib fracture occurred. One case of toxic death (grade 5) has been reported. Median OS was 39 months. At the univariate analysis, lesion diameter <= 18 mm correlated significpntly with a longer LPFS (p = 0.001). At the multivariate analysis, lesion diameter < 18 mm was predictive for longer LPFS (p = 0.006). Also, oligometastases from primary colorectal cancer was a significant predictive factor for worse LPFS (p = 0.041) and progression-free survival (p = 0.04). Conclusions: To our knowledge, the current study represents the largest series on the use of SBRT 30 Gy single dose for lung metastases. Our results confirm the effectiveness and safety of this schedule administered in selected oligometastatic patients. Further prospective series could better validate these results.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 24 条
  • [1] Agolli L, 2015, ANTICANCER RES, V35, P6239
  • [2] Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
    Binkley, Michael S.
    Trakul, Nicholas
    Jacobs, Lisa Rose
    von Eyben, Rie
    Quynh-Thu Le
    Maxim, Peter G.
    Loo, Billy W., Jr.
    Shultz, David Benjamin
    Diehn, Maximilian
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (05): : 1044 - 1052
  • [3] Outcomes of Single Fraction Stereotactic Ablative Radiotherapy for Lung Metastases
    Filippi, Andrea R.
    Badellino, Serena
    Guarneri, Alessia
    Levis, Mario
    Botticella, Angela
    Mantovani, Cristina
    Ragona, Riccardo
    Racca, Patrizia
    Buffoni, Lucio
    Novello, Silvia
    Ricardi, Umberto
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2014, 13 (01) : 37 - 45
  • [4] Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning
    Fritz, Peter
    Kraus, Hans-Joerg
    Blaschke, Thomas
    Muehlnickel, Werner
    Strauch, Konstantin
    Engel-Riedel, Walburga
    Chemaissani, Assad
    Stoelben, Erich
    [J]. LUNG CANCER, 2008, 60 (02) : 193 - 199
  • [5] Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
    Gomez, Daniel R.
    Blumenschein, George R., Jr.
    Lee, J. Jack
    Hernandez, Mike
    Ye, Rong
    Camidge, D. Ross
    Doebele, Robert C.
    Skoulidis, Ferdinandos
    Gaspar, Laurie E.
    Gibbons, Don L.
    Karam, Jose A.
    Kavanagh, Brian D.
    Tang, Chad
    Komaki, Ritsuko
    Louie, Alexander V.
    Palma, David A.
    Tsao, Anne S.
    Sepesi, Boris
    William, William N.
    Zhang, Jianjun
    Shi, Qiuling
    Wang, Xin Shelley
    Swisher, Stephen G.
    Heymach, John V.
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1672 - 1682
  • [6] PREDICTORS OF LOCAL CONTROL AFTER SINGLE-DOSE STEREOTACTIC IMAGE-GUIDED INTENSITY-MODULATED RADIOTHERAPY FOR EXTRACRANIAL METASTASES
    Greco, Carlo
    Zelefsky, Michael J.
    Lovelock, Michael
    Fuks, Zvi
    Hunt, Margie
    Rosenzweig, Kenneth
    Zatcky, Joan
    Kim, Balem
    Yamada, Yoshiya
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (04): : 1151 - 1157
  • [7] Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy
    Guckenberger, Matthias
    Klement, Rainer J.
    Allgaeuer, Michael
    Andratschke, Nicolaus
    Blanck, Oliver
    Boda-Heggemann, Judit
    Dieckmann, Karin
    Duma, Marciana
    Ernst, Iris
    Ganswindt, Ute
    Hass, Peter
    Henkenberens, Christoph
    Holy, Richard
    Imhoff, Detlef
    Kahl, Henning K.
    Krempien, Robert
    Lohaus, Fabian
    Nestle, Ursula
    Nevinny-Stickel, Meinhard
    Petersen, Cordula
    Semrau, Sabine
    Streblow, Jan
    Wendt, Thomas G.
    Wittig, Andrea
    Flentje, Michael
    Sterzing, Florian
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 118 (03) : 485 - 491
  • [8] Stereotactic single high dose irradiation of lung tumors under respiratory gating
    Hara, R
    Itami, J
    Kondo, T
    Aruga, T
    Abe, Y
    Ito, M
    Fuse, M
    Shinohara, D
    Nagaoka, T
    Kobiki, T
    [J]. RADIOTHERAPY AND ONCOLOGY, 2002, 63 (02) : 159 - 163
  • [9] Hof H., 2017, STRAHLENTHER ONKOL, V12, P673
  • [10] Increasing Radiation Therapy Dose Is Associated With Improved Survival in Patients Undergoing Stereotactic Body Radiation Therapy for Stage I Non-Small-Cell Lung Cancer
    Koshy, Matthew
    Malik, Renuka
    Weichselbaum, Ralph R.
    Sher, David J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (02): : 344 - 350